Yogesh Kembhavi
Overview
Explore the profile of Yogesh Kembhavi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bajpai J, Sarkar L, Rath S, Pawar A, Chandrashekharan A, Panda G, et al.
JCO Glob Oncol
. 2025 Feb;
11:e2400142.
PMID: 39913876
Purpose: Outcomes of adolescents and young adults (AYA) with bone sarcomas including osteosarcoma (OGS) and Ewing sarcoma (ES) are affected by various factors including inadvertent previous treatment and poor compliance....
2.
Bajpai J, Sarkar L, Rath S, Chandrasekharan A, Panda G, Jakar D, et al.
Cancer
. 2024 Sep;
131(1):e35547.
PMID: 39297373
Background: The care of adolescents and young adults (AYAs) with bone sarcomas involves unique challenges. The objectives of this study were to identify challenges and evaluate long-term outcomes of these...
3.
Gardi N, Chaubal R, Parab P, Pachakar S, Kulkarni S, Shet T, et al.
Cancer Res Commun
. 2024 Feb;
4(2):404-417.
PMID: 38315150
Significance: In germline BRCA1 mutated and BRCA wild-type patients, TNBC shows a branching evolutionary pattern of mutations with a single founding clone, are polyclonal throughout their disease course, and have...
4.
Nag S, Dikshit R, Desai S, Mane A, Mhatre S, Neve R, et al.
Sci Rep
. 2023 Aug;
13(1):13551.
PMID: 37599285
The risk factors for breast cancer have been defined in several studies but there is deficient data for specific subtypes. We report here the pathological characteristics of a breast cancer...
5.
Rath S, Elamarthi P, Parab P, Gulia S, Nandhana R, Mokal S, et al.
PLoS One
. 2021 Jul;
16(7):e0253722.
PMID: 34292933
Background: There is scant data from India on efficacy and safety of palbociclib and ribociclib in routine clinical practice. Methods: This retrospective, observational, single institution study included patients with estrogen...
6.
Gota V, Nookala M, Bonda A, Karanam A, Shriyan B, Kembhavi Y, et al.
Cancer Med
. 2021 Apr;
10(9):3068-3076.
PMID: 33826243
Background: Paclitaxel is dosed according to body surface area (BSA) but there is scant information on actual drug exposure in overweight and obese patients. Methods: Early breast cancer patients receiving...
7.
Ghosh J, Joy Phillip D, Ghosh J, Bajpai J, Gulia S, Parmar V, et al.
Indian J Cancer
. 2021 Mar;
59(3):387-393.
PMID: 33753616
Background: There is limited access to 1 year of adjuvant trastuzumab in resource-constrained settings. Most randomized studies have failed to prove non-inferiority of shorter durations of adjuvant trastuzumab compared to...
8.
Khadilkar S, Bopanna M, Parab P, Gulia S, Chhasatia S, Kothari S, et al.
J Obstet Gynaecol India
. 2020 Oct;
70(5):371-375.
PMID: 33041555
Background: Breast cancer is the most common malignancy in Indian women. There is scant data from Indian hospital-based populations on the prevalence of risk factors of this disease. We performed...
9.
Bajpai J, Panda P, Kagwade S, Govilkar M, Velaskar S, Kembhavi Y, et al.
South Asian J Cancer
. 2018 Mar;
7(1):37-41.
PMID: 29600233
Aim: The aim is to translate and validate the European Organization for Research and Treatment for Cancer (EORTC) ovarian cancer (OC) module (OV-28) into Hindi and Marathi to use for...
10.
Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, et al.
J Clin Oncol
. 2018 Feb;
36(16):1548-1555.
PMID: 29432076
Purpose We compared the efficacy and toxicity of neoadjuvant chemotherapy followed by radical surgery versus standard cisplatin-based chemoradiation in patients with locally advanced squamous cervical cancer. Patients and Methods This...